Animal health company Elanco (NYSE:ELAN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales ...

GREENFIELD, IN / ACCESS Newswire / February 25, 2025 / Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has ...

Elanco has struck an agreement to distribute a vaccine that may protect cattle for up to 12 months against bird flu ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...

Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...

Elanco Animal Health (NYSE:ELAN) stock falls as the company reports mixed Q4 2024 results, and sets 2025 outlook below consensus due to forex headwinds. Read more here.

Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.

Elanco Animal Health (ELAN) has received a warning letter from the FDA related to promotional materials for its canine drug ...

Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.

Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.